A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain
| Autor: | Sandie Reader, Michael A Goulder, Sue Aspley, Christopher J. Hawkey, Nicola Hill, Michael Doherty, Iain Gibb |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Knee Joint Immunology Population Pain Ibuprofen Nonprescription Drugs Osteoarthritis Drug Administration Schedule General Biochemistry Genetics and Molecular Biology law.invention Hemoglobins Double-Blind Method Rheumatology Blood loss Randomized controlled trial law Internal medicine medicine Humans Immunology and Allergy education Acetaminophen Aged Pain Measurement Aged 80 and over education.field_of_study Dose-Response Relationship Drug business.industry organic chemicals Analgesics Non-Narcotic Middle Aged Osteoarthritis Knee medicine.disease Drug Combinations Treatment Outcome Knee pain Ibuprofen/paracetamol Anesthesia Chronic Disease Female medicine.symptom business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 70:1534-1541 |
| ISSN: | 0003-4967 |
| Popis: | To compare the efficacy and safety of single versus combination non-prescription oral analgesics in community-derived people aged 40 years and older with chronic knee pain.A randomised, double-blind, four-arm, parallel-group, active controlled trial investigating short-term (day 10) and long-term (week 13) benefits and side-effects of four regimens, each taken three times a day: ibuprofen (400 mg); paracetamol (1000 mg); one fixed-dose combination tablet (ibuprofen 200 mg/paracetamol 500 mg); two fixed-dose combination tablets (ibuprofen 400 mg/paracetamol 1000 mg).There were 892 participants (mean age 60.6, range 40-84 years); 63% had radiographic knee osteoarthritis and 85% fulfilled American College of Rheumatology criteria for osteoarthritis. At day 10, two combination tablets were superior to paracetamol (p0.01) for pain relief (determined by mean change from baseline in WOMAC pain; n=786). At 13 weeks, significantly more participants taking one or two combination tablets rated their treatment as excellent/good compared with paracetamol (p=0.015, p=0.0002, respectively; n=615). The frequency of adverse events was comparable between groups. However, by 13 weeks, decreases in haemoglobin (≥1 g/dl) were observed in some participants in all groups. Twice as many participants taking two combination tablets had this decrease compared with those on monotherapy (p0.001; paracetamol, 20.3%; ibuprofen, 19.6%; one or two combination tablets, 24.1%, 38.4%, respectively).Ibuprofen/paracetamol combination analgesia, at non-prescription doses, confers modest short-term benefits for knee pain/osteoarthritis. However, in this population, paracetamol 3 g/day may cause similar degrees of blood loss as ibuprofen 1200 mg/day, and the combination of the two appears to be additive. Study no ISRCTN77199439. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|